Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.9 - $8.02 $1.29 Million - $1.75 Million
218,302 Added 54.86%
616,220 $4.02 Million
Q1 2024

May 15, 2024

SELL
$7.5 - $12.07 $1.46 Million - $2.35 Million
-195,084 Reduced 32.9%
397,918 $3.3 Million
Q2 2023

Aug 14, 2023

SELL
$9.99 - $18.27 $9.88 Million - $18.1 Million
-989,249 Reduced 62.52%
593,002 $7.45 Million
Q1 2023

May 15, 2023

SELL
$15.0 - $22.76 $541,530 - $821,681
-36,102 Reduced 2.23%
1,582,251 $26.1 Million
Q4 2022

Feb 14, 2023

SELL
$14.16 - $24.02 $19.1 Million - $32.4 Million
-1,349,092 Reduced 45.46%
1,618,353 $24.2 Million
Q3 2022

Nov 14, 2022

SELL
$18.07 - $31.37 $2.26 Million - $3.93 Million
-125,281 Reduced 4.05%
2,967,445 $66.4 Million
Q2 2022

Aug 15, 2022

SELL
$13.31 - $34.88 $12.8 Million - $33.4 Million
-957,962 Reduced 23.65%
3,092,726 $51.8 Million
Q1 2022

May 16, 2022

BUY
$20.26 - $32.36 $330,886 - $528,503
16,332 Added 0.4%
4,050,688 $121 Million
Q4 2021

Feb 14, 2022

BUY
$26.0 - $37.03 $25.6 Million - $36.4 Million
983,654 Added 32.24%
4,034,356 $124 Million
Q3 2021

Nov 15, 2021

BUY
$29.75 - $37.99 $5.85 Million - $7.47 Million
196,662 Added 6.89%
3,050,702 $96.2 Million
Q2 2021

Aug 16, 2021

BUY
$27.5 - $38.19 $8.56 Million - $11.9 Million
311,421 Added 12.25%
2,854,040 $104 Million
Q1 2021

May 17, 2021

BUY
$32.52 - $61.53 $47 Million - $89 Million
1,446,339 Added 131.93%
2,542,619 $87.9 Million
Q4 2020

Feb 16, 2021

BUY
$35.51 - $54.03 $826,353 - $1.26 Million
23,271 Added 2.17%
1,096,280 $45.6 Million
Q3 2020

Nov 16, 2020

BUY
$32.81 - $45.1 $35.2 Million - $48.4 Million
1,073,009 New
1,073,009 $45.7 Million

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $577M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Driehaus Capital Management LLC Portfolio

Follow Driehaus Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Driehaus Capital Management LLC with notifications on news.